SCHEMBL7652792

SCHEMBL7652792

CC(CNS(=O)(=O)C(C)C)C1CCNCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 5/20 0.52
GRIA2 P42262 3/20 0.52
GRIA3 P42263 2/20 0.52
LMNA P02545 1/20 0.34
CYP3A4 P08684 1/20 0.34
GABRA1 P14867 1/20 0.34
TSHR P16473 1/20 0.34
GABRG2 P18507 1/20 0.34
NFKB1 P19838 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA5 P31644 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRA6 Q16445 1/20 0.34
GRIA4 P48058 11/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
SLC6A3 Q01959 1/20 0.33
CPN1 P15169 1/20 0.32
CPB2 Q96IY4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22455469 0.83 GRIA1 (0.37) GRIA1GRIA2GRIA3LMNACYP3A4
SCHEMBL7469264 0.79 GRIA1 (0.52) GRIA1GRIA2GRIA3GRIA4
SCHEMBL7469005 0.79 GRIA1 (0.52) GRIA1GRIA2GRIA3GRIA4
SCHEMBL7477390 0.78 GRIA1 (0.51) GRIA1GRIA2GRIA3GRIA4
SCHEMBL7469450 0.76 GRIA1 (0.59) GRIA1GRIA2GRIA3GRIA4
SCHEMBL13812326 0.75 NPY5R (0.40) GRIA1LMNACYP3A4GABRA1TSHR
Hydrochloric Acid SCHEMBL6409050 0.74 GNAI3 (0.40) GRIA1LMNACYP3A4GABRA1TSHR
SCHEMBL7474858 0.73 GRIA1 (0.44) GRIA1GRIA2GRIA3LMNATSHR
SCHEMBL7475447 0.73 GRIA1 (0.47) GRIA1GRIA2GRIA3GRIA4
SCHEMBL12989697 0.73 SLC6A2 (0.38) LMNACYP3A4GABRA1TSHRGABRG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6355655-B1 TREATING A COGNITIVE DISORDER, A NEURO-DEGENERATIVE DISORDER; AGE-RELATED DEMENTIA; AGE-INDUCED MEMORY IMPAIRMENT; A MOVEMENT DISORDER, ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT HYPERACTIVITY DISORDER; PSYCHOSIS; COGNITIVE DEFICITS ELI LILLY AND COMPANY 2002-03-12 US disclosed
EP-1100498-A4 HETEROCYCLIC SULPHONAMIDE DERIVATIVES LILLY CO ELI (US) 2001-10-24 EP disclosed
EP-1100498-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES Eli Lilly & Company (US) 2001-05-23 EP disclosed
WO-2000006159-A1 HETEROCYCLIC SULPHONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2000-02-10 WO disclosed